Gland Pharma Closing Bell Updates: Share Price Drops on Profit Booking
Gland Pharma (NSE: GLAND) share price closed at ₹2,250.00, down 2.72% today, as profit booking hit the stock after recent strong gains.
Gland Pharma (NSE: GLAND) experienced a downturn in Friday's trading session, opening at ₹2,315.00 before touching an intraday high of ₹2,337.50. However, the momentum quickly faded, pushing the stock to a low of ₹2,230.00 before settling at a closing Last Traded Price (LTP) of ₹2,250.00. This represented a 2.72% decline from its previous close of ₹2,313.00. Trading volume for the day stood at 218,609 shares, significantly lower than its typical average daily volume, which often ranges between 575,000 and 868,000 shares, suggesting reduced participation in the downward movement.
| GLAND – Stock Updates as of (4:24PM, 29 May 2026) | |||
LTP ₹2,250.00 | Open ₹2,315.00 | High ₹2,337.50 | Low ₹2,230.00 |
52W High ₹0.00 | 52W Low ₹0.00 | Volume 218,609 | % Chg -2.72% |
Session Highlights
The trading day began with an attempt to extend recent gains, as Gland Pharma briefly traded above its opening price. However, this early momentum was short-lived, and the stock soon entered a steady decline through the mid-session. The selling pressure intensified into the afternoon, pushing the price towards its intraday low. Despite this, a minor recovery was observed in the late session, preventing a steeper fall, though it wasn't enough to reverse the overall negative sentiment that prevailed.
Drivers & Developments
Today's decline appears to be largely a result of profit booking following a period of strong upward movement, rather than any fresh negative corporate developments. The company recently reported robust Q4 FY26 results on May 15, 2026, with consolidated net profit surging by 96.6% year-on-year and revenue growing by 22.3%. This impressive performance, coupled with a recommended final dividend of ₹20 per share, had driven the stock to hit fresh 52-week highs earlier in May. Several analysts had also reiterated "Buy" ratings and raised their price targets for Gland Pharma, citing factors like the turnaround in its European unit Cenexi, new product launches, and strong growth in its contract development and manufacturing (CDMO) business. While the company had a scheduled analyst and institutional investor meeting with Ashmore Investment Management on May 29, 2026, no specific details emerged to definitively link it to today's price action, suggesting the fall was more technical given the prior rallies.
52-Week Context
Today's closing price of ₹2,250.00 places Gland Pharma below its 52-week high of ₹2,396.00, which it achieved earlier in May 2026. However, it remains significantly above its 52-week low of ₹1,512.10. The stock has delivered substantial returns over the past year, with gains of over 50%, highlighting its strong performance leading up to today's correction.
What to Watch Tomorrow
Investors will be closely watching for any fresh analyst commentary or corporate announcements that could provide direction. Key support levels around the ₹2,230 mark will be crucial to monitor, while resistance could be encountered near the ₹2,300 level if buying interest resurfaces.
Disclaimer: The information provided in this article is based on news reports and is not intended as investment advice. Investing in stocks involves risk. LatestLY advises its readers to consult with a financial advisor before making any investment decisions.
(The above story first appeared on LatestLY on May 29, 2026 04:25 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
